The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MMP1 protein]; ilomastat inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MMP1 mRNA]
ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TIMP1 mRNA]; ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TIMP1 protein]
APP protein mutant form results in decreased abundance of Tryptophan PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Tryptophan]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA Tryptophan results in increased expression of CYP1A1 mRNA
Tryptophan results in increased expression of CYP1B1 mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA
IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] Tryptophan results in increased expression of IGFBP1 mRNA
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Tryptophan; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Tryptophan]
Tryptophan results in increased expression of PRL mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]